Costimulation, a surprising connection for immunotherapy.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

7 citing papers in PubMed.

1. Dual agonism and selective T-cell depletion activity of a PD-1-directed antibody for treating autoimmune diseases.mAbs · 2026
   Article
2. Immune Checkpoint Inhibitors in 10 Years: Contribution of Basic Research and Clinical Application in Cancer Immunotherapy.Immune network · 2022
   Review
3. The MHC Class-I Transactivator NLRC5: Implications to Cancer Immunology and Potential Applications to Cancer Immunotherapy.International journal of molecular sciences · 2021
   Review
4. 4-1BB Agonism Averts TIL Exhaustion and Licenses PD-1 Blockade in Glioblastoma and Other Intracranial Cancers.Clinical cancer research : an official journal of the American Association for Cancer Research · 2020
   Article
5. The landscape of novel and complementary targets for immunotherapy: an analysis of gene expression in the tumor microenvironment.Oncotarget · 2019
   Article
6. Efficacy of PD-1 blockade in cervical cancer is related to a CD8Journal for immunotherapy of cancer · 2019
   Article
7. Irreversible electroporation of locally advanced pancreatic cancer transiently alleviates immune suppression and creates a window for antitumor T cell activation.Oncoimmunology
   Article

Corrections and comments

• Comment on
  T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition.2017
• Comment on
  Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent.2017

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as